| Cash flow (USD) | FY 2025 ended Dec 31, 2025 | FY 2024 ended Dec 31, 2024 | FY 2023 ended Dec 31, 2023 | FY 2022 ended Dec 31, 2022 | FY 2021 ended Dec 31, 2021 | FY 2020 ended Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Net income | 20.64B | 10.59B | 5.24B | 6.24B | 5.58B | 6.19B |
| Depreciation and amortization | 2.00B | 1.77B | 1.53B | 1.52B | 1.55B | 1.32B |
| Stock-based compensation | 626.00M | 646.00M | 629.00M | 371.10M | 342.80M | 308.10M |
| Cash from operations | 16.81B | 8.82B | 4.24B | 7.59B | 7.37B | 6.50B |
| Acquisitions | -327.20M | -747.40M | -849.30M | |||
| Cash from investing | -10.97B | -9.30B | -7.15B | -3.76B | -2.87B | -2.26B |
| Dividends paid | -5.38B | -4.68B | -4.07B | -3.54B | -3.09B | -2.69B |
| Share buybacks | -4.11B | -2.50B | -750.00M | -1.50B | -1.25B | -500.00M |
| Net debt issued | 12.39B | 10.75B | 3.96B | -1.56B | 505.40M | 1.79B |
| Cash from financing | -2.21B | 1.23B | 3.50B | -5.41B | -4.13B | -3.14B |
| Net change in cash | 4.00B | 449.00M | 752.00M | -1.75B | 161.40M | 1.32B |
From Eli Lilly's 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read cash flow or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.